Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06497959

Study of Placental Vascularization Using Contrast Ultrasound

Preeclampsia and intrauterine growth restriction (IUGR) are two principal complications of pregnancy. These diseases are related to placental dysfunction nevertheless knowledge of its pathophysiological mechanisms remains inadequate.

No etiological treatment for these pathologies is available. Inducing birth is the only way to prevent the occurrence of these complications (such as fetal death in utero.

Therefore, a better understanding of placental vascularization under pathological and physiological conditions is necessary. This placental vascularization evolves throughout gestation. Histological studies have improved our knowledge of placental vascular pathologies; however, these are ex vivo data that only provide an incomplete reflection of placental function. In vivo placental studies are therefore essential to understand the mechanisms of placental perfusion. Currently, these studies are limited because the available tools (such as placental Doppler) do not allow for the separate study of maternal placental flow from fetal flow. However, histological evidence clearly establishes maternal placental vascular involvement in IUGR. It would therefore be interesting to study maternal and fetal placental vascularization separately. The development of new in vivo imaging exploration techniques will help to better understand placental pathologies.

In obstetrics, CES would offer the opportunity to study in vivo placental vascularization in a segmented manner (maternal versus fetal side independently) since the microbubbles do not cross the placental barrier. Animal studies show no toxic effects on fetal development nor any crossing of the placental barrier. In humans, the innovative use of this contrast agent has allowed for a better understanding of placental vascularization in the first trimester of pregnancy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Fetal Growth Restriction Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases and Pregnancy Complications Fetal Diseases Fetal Growth Retardation Growth Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Pregnancy Complications Urogenital Diseases

Age range

18 year–64 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

About this study

The primary objective is to compare placental contrast ultrasound in patients with medical termination of pregnancy at gestational age 16 weeks - 38 weeks+ 6 days between two groups: the fetal growth restriction one and the no fetal growth restriction.

Methods and analysis: This is a monocentric, prospective comparative, non-randomized, feasibility, open and interventional study. The investigators will include 30 women with medical termination of pregnancy divided in two groups: fetal growth restriction one and the no fetal growth restriction. Women are informed and recruited in the Fetal Medicine units in Nancy, over a period of 48 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult woman (age ≥18 years),
  • Gestational age between 16 GW + 0 days and 38 GW + 6 days,
  • Singleton pregnancy,
  • Whose request of a medical termination of pregnancy (IMG) has been formulated and accepted in a written form by the Centre Pluridisciplinaire de Diagnostic Prénatal (CPDPN) of the Centre Hospitalier Régional Universaitaire (CHRU) de Nancy,
  • Affiliated to the social security system or benefit from such a system,
  • Having received full information and having signed an informed consent form.

Criteria specific to patients in the "growth restriction" group:

  • Severe growth restriction defined by an estimation of foetal weight below the 3rd percentile using ultrasound performed no more than 15 days prior to the IMG (the diagnosis must be established at the time of the request for IMG in routine care).

Exclusion criteria

  • Person who do not speak French
  • Any medical condition contraindicating the administration of SonoVue, in particular:
  • Hypersensitivity to sulfur hexafluoride or to one of the other components of SonoVue® such as polyethylene glycol (PEG),
  • Women with recent acute coronary syndrome or unstable ischaemic heart disease,
  • Women with a right-to-left shunt, severe pulmonary arterial hypertension (pulmonary arterial pressure > 90 mmHg), uncontrolled systemic hypertension and women suffering from respiratory distress syndrome.
  • Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code:
  • Breast-feeding mother
  • Minor (not emancipated)
  • An adult subject to a legal protection (guardianship, curatorship, safeguard of justice)
  • An adult unable to give consent
  • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1

Treatment and study plan

SonoVue

Drug

Placental contrast ultrasound using SonoVue by maternal intravenous injection

Primary outcomes

  1. The measurement of signal strength

    Time frame: 1 day

    The measurement of signal strength (in arbitrary units) in the Inter-Villi Space of the placetna ,obtained by contrast ultrasound, in women who have confirmed a medical termination of pregnancy according to the group defined by fetal weight in percentile as a function of term. Severe Intrauterine Growth Restriction (IUGR) is defined as a weight below the 3rd percentile for gestational age.For each group, these parameters will be obtained by qualitative analysis (i.e. presence/absence of contrast medium passage) and semi-quantitative analysis (enhancement percentage, area under the curve, time to peak, slopes -wash-in rate and wash-out rate, etc.) using dedicated software VueBox, BRACCO

Secondary outcomes

  1. Measurement of the vascularization parameters of the Inter-Villi Space: infusion kinetics.

    Time frame: 1 day

    Measurement of the vascularization parameters of the Inter-Villi Space : infusion kinetics by ultrasound with a contrast agent: SonoVue ®.

  2. Measurement of the vascularization parameters of the umbilical cord: infusion kinetics

    Time frame: 1 day

    Measurement of the vascularization parameters of the umbilical cord: infusion kinetics by ultrasound with a contrast agent: SonoVue ®.

  3. Measurement of the placenta vascularization using histological analysis

    Time frame: through study completion, on average of 24 months

    Measurement of the placenta vascularization using histological analysis according to the Amsterdam Standardised Analysis criteria.

  4. Comparison of of the placenta vascularization using histological analysis and the measurement of the vascularization parameters of the Inver-Villi Space.

    Time frame: through study completion, on average of 24 months

    Measurement of the placenta vascularization using histological analysis according to the Amsterdam Standardised Analysis criteria and the vascularization parameters of the umbilical cord: infusion kinetics by ultrasound with a contrast agent: SonoVue ®.

Study contacts

Contact information is provided by the study sponsor or research team.

Juliette LEFEBVRE, Junior doctor

CONTACT

[email protected]

Matthieu DAP, Doctor

CONTACT

[email protected]

+333 83 34 36 11

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Contribution of Contrast-Enhanced Ultrasound (CES) in the Fetal-placental Circulation Study

Acronym: EVUPACUS

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jul 12, 2024
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.